Hansa Biopharma, Svært at tage seriøst når kursen er 114
-
-
Hansa nok dette som har givet kursfaldet progress and outlook remain most important for Hansa. In the GBS (Guillain-Barré syndrome) trial, 10 out of 30 patients are now enrolled (8 at the earlier Q1), and in the important, (complements Ideflirix) AMR (Antibody-mediated kidney transplant rejection) trial, 12 out of 30 patients are now enrolled (9 at the earlier Q1). The enrolment rate appears to be modest, especially as Hansa's earlier communication is that both studies are expected to be fully enrolled during H2 2021, and this is now modified to H2 2021/H2 2022.
Vi
Morten -
Jep, forpestet af shorting....nu 2,58% .... Hader det pengegriske skidt
-
Hansa - Analyseopdateringer:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind